Sunovion scores on PhI­II Parkin­son's study, shoot­ing for show­down with Acor­da; Puma out-li­cens­es ner­a­tinib to Is­raeli biotech

→ Sunovion Phar­ma­ceu­ti­cals has post­ed pos­i­tive top-line da­ta from their Phase III study for OFF episodes of Parkin­son’s dis­ease. Ac­cord­ing to re­searchers apo­mor­phine hit the pri­ma­ry: a sta­tis­ti­cal­ly sig­nif­i­cant mean re­duc­tion in the Move­ment Dis­or­der So­ci­ety Uni­fied Parkin­son’s Dis­ease Rat­ing Scale (MDS-UP­DRS) Part III score. They added that the drug al­so scored on a key sec­ondary. Sunovion now plans to hus­tle the drug to the FDA soon, which may well set up a con­fronta­tion with a ri­val drug from the strug­gling Acor­da $ACOR, now ru­mored to be on the sales block.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER